Informações:
Falhas:
ID
41817
Descrição
Nitroglycerin in Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01210378
Link
https://clinicaltrials.gov/show/NCT01210378
Palavras-chave
Versões (3)
- 21/01/2021 21/01/2021 - Ahmed Rafee, MD
- 21/01/2021 21/01/2021 - Ahmed Rafee, MD
- 22/01/2021 22/01/2021 - Sarah Riepenhausen
Titular dos direitos
Maastricht Radiation Oncology
Transferido a
22 de janeiro de 2021
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Non Small Cell Lung Cancer (NSCLC) NCT01210378
Eligibility Non Small Cell Lung Cancer (NSCLC) NCT01210378
- StudyEvent: Eligibility
Similar models
Eligibility Non Small Cell Lung Cancer (NSCLC) NCT01210378
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
non-small cell lung cancer stage ib-iv amenable for radiotherapy with curative intent.
Item
non-small cell lung cancer stage ib-iv amenable for radiotherapy with curative intent.
boolean
C0007131 (UMLS CUI [1,1])
C1300072 (UMLS CUI [1,2])
C3900053 (UMLS CUI [1,3])
C1522449 (UMLS CUI [1,4])
C1276305 (UMLS CUI [1,5])
C1300072 (UMLS CUI [1,2])
C3900053 (UMLS CUI [1,3])
C1522449 (UMLS CUI [1,4])
C1276305 (UMLS CUI [1,5])
(stage iv patients with oligometastic (1-4 metastases) nsclc are regularly treated radically in the iknl region).
Item
(stage iv patients with oligometastic (1-4 metastases) nsclc are regularly treated radically in the iknl region).
boolean
C0007131 (UMLS CUI [1,1])
C1300072 (UMLS CUI [1,2])
C0439807 (UMLS CUI [1,3])
C0449788 (UMLS CUI [1,4])
C0027627 (UMLS CUI [1,5])
C1300072 (UMLS CUI [1,2])
C0439807 (UMLS CUI [1,3])
C0449788 (UMLS CUI [1,4])
C0027627 (UMLS CUI [1,5])
patients not included in the pet-boost or the lucanix trial.
Item
patients not included in the pet-boost or the lucanix trial.
boolean
C2348568 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,2])
who performance status 0-2.
Item
who performance status 0-2.
boolean
C1298650 (UMLS CUI [1])
willing and able to comply with the study prescriptions.
Item
willing and able to comply with the study prescriptions.
boolean
C0525058 (UMLS CUI [1])
18 years or older.
Item
18 years or older.
boolean
C0001779 (UMLS CUI [1])
ability to give and having given written informed consent before patient registration.
Item
ability to give and having given written informed consent before patient registration.
boolean
C0021430 (UMLS CUI [1,1])
C0085732 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2])
C0085732 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2])
no recent (< 3 months) severe cardiac disease (nyha class >1) (congestive heart failure, infarction).
Item
no recent (< 3 months) severe cardiac disease (nyha class >1) (congestive heart failure, infarction).
boolean
C0018799 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,4])
C1275491 (UMLS CUI [2])
C0018802 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
C0332185 (UMLS CUI [3,4])
C0027051 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C0332185 (UMLS CUI [4,4])
C0205082 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,4])
C1275491 (UMLS CUI [2])
C0018802 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
C0332185 (UMLS CUI [3,4])
C0027051 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C0332185 (UMLS CUI [4,4])
no radiotherapy in 4 weeks prior to this study.
Item
no radiotherapy in 4 weeks prior to this study.
boolean
C1522449 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
no treatment with investigational drugs in 4 weeks prior to or during this study.
Item
no treatment with investigational drugs in 4 weeks prior to or during this study.
boolean
C0013230 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
C0332197 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
no known allergy to nitroglycerin or nitroglycerin patch.
Item
no known allergy to nitroglycerin or nitroglycerin patch.
boolean
C0017887 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0017887 (UMLS CUI [2,1])
C0991556 (UMLS CUI [2,2])
C0020517 (UMLS CUI [2,3])
C0332197 (UMLS CUI [2,4])
C0020517 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0017887 (UMLS CUI [2,1])
C0991556 (UMLS CUI [2,2])
C0020517 (UMLS CUI [2,3])
C0332197 (UMLS CUI [2,4])
no known allergy to iodine based contrast agents
Item
no known allergy to iodine based contrast agents
boolean
C4022917 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,2])
no use of levitra, viagra or cialis at the time of application of the nitroglycerin patch.
Item
no use of levitra, viagra or cialis at the time of application of the nitroglycerin patch.
boolean
C1317775 (UMLS CUI [1,1])
C0017887 (UMLS CUI [1,2])
C0991556 (UMLS CUI [1,3])
C0663448 (UMLS CUI [1,4])
C0332197 (UMLS CUI [1,5])
C1317775 (UMLS CUI [2,1])
C0017887 (UMLS CUI [2,2])
C0991556 (UMLS CUI [2,3])
C1174890 (UMLS CUI [2,4])
C0332197 (UMLS CUI [2,5])
C1317775 (UMLS CUI [3,1])
C0017887 (UMLS CUI [3,2])
C0991556 (UMLS CUI [3,3])
C0967376 (UMLS CUI [3,4])
C0332197 (UMLS CUI [3,5])
C0017887 (UMLS CUI [1,2])
C0991556 (UMLS CUI [1,3])
C0663448 (UMLS CUI [1,4])
C0332197 (UMLS CUI [1,5])
C1317775 (UMLS CUI [2,1])
C0017887 (UMLS CUI [2,2])
C0991556 (UMLS CUI [2,3])
C1174890 (UMLS CUI [2,4])
C0332197 (UMLS CUI [2,5])
C1317775 (UMLS CUI [3,1])
C0017887 (UMLS CUI [3,2])
C0991556 (UMLS CUI [3,3])
C0967376 (UMLS CUI [3,4])
C0332197 (UMLS CUI [3,5])
no conditions necessitating the use of ergot alkaloids, alpha blockers (eg tamsulosine), betablockers or calcium channel blockers on the day of nitroglycerin patch application).
Item
no conditions necessitating the use of ergot alkaloids, alpha blockers (eg tamsulosine), betablockers or calcium channel blockers on the day of nitroglycerin patch application).
boolean
C0014707 (UMLS CUI [1,1])
C3146298 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0001641 (UMLS CUI [2,1])
C3146298 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0304516 (UMLS CUI [3,1])
C3146298 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
C0006684 (UMLS CUI [4,1])
C3146298 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C3146298 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0001641 (UMLS CUI [2,1])
C3146298 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0304516 (UMLS CUI [3,1])
C3146298 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
C0006684 (UMLS CUI [4,1])
C3146298 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
no other active malignancy.
Item
no other active malignancy.
boolean
C0006826 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
no major surgery (excluding diagnostic procedures like eg mediastinoscopy) in previous 4 weeks.
Item
no major surgery (excluding diagnostic procedures like eg mediastinoscopy) in previous 4 weeks.
boolean
C0679637 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0025065 (UMLS CUI [2,2])
C0332197 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0025065 (UMLS CUI [2,2])
adequate renal function: calculated creatinine clearance at least 60ml/min.
Item
adequate renal function: calculated creatinine clearance at least 60ml/min.
boolean
C0373595 (UMLS CUI [1])